GlassScriptPhysician profile
Andrew Herman
NPI 1003260217
$7,172.84
in general payments reported to CMS, 2019-2025
18 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $104 · 2021: $781 · 2022: $2,609 · 2023: $549 · 2024: $1,457 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.04 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,613.60 | 2019-2025 | |
| Boston Scientific Corporation | $1,095.07 | 2021-2025 | Resolution Clip, Overstitch Nxt Endoscopic Suturing System, Spyglass |
| Takeda Pharmaceuticals U.S.A., INC. | $435.18 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $287.61 | 2023-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $267.36 | 2019-2024 | |
| Apollo Endosurgery US INC | $227.57 | 2022 | |
| Gilead Sciences, INC. | $193.91 | 2020-2021 | |
| Pfizer INC. | $180.99 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $162.49 | 2025 | Vowst, Zenpep |
| Ardelyx, INC. | $152.18 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $113.79 | 2024-2025 | Dupixent |
| Erbe USA INC | $88.59 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $77.99 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $66.45 | 2024-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $53.49 | 2023-2024 | Zeposia |
| Pentax of America, INC. | $17.39 | 2022 | |
| Merck Sharp & Dohme LLC | $14.18 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.